Detalhe da pesquisa
1.
Anemia-related response end points in myelofibrosis clinical trials: current trends and need for renewed consensus.
Future Oncol
; 20(11): 703-715, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38318719
2.
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
Cancer
; 129(23): 3746-3760, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37622738
3.
Survival outcomes for patients with multiple myeloma in France: A retrospective cohort study using the Système National des Données de Santé national healthcare database.
Eur J Haematol
; 111(1): 125-134, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37199133
4.
Drivers of physician decision-making and patient perspectives across lines of therapy in multiple myeloma in the USA.
Future Oncol
; 19(22): 1549-1562, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37283044
5.
Real-world patient-reported outcomes and concordance between patient and physician reporting of side effects across lines of therapy in multiple myeloma within the USA.
Support Care Cancer
; 31(6): 371, 2023 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37268868
6.
Correction to: Development of a conceptual model and patient-reported outcome measures for assessing symptoms and functioning in patients with heart failure.
Qual Life Res
; 29(10): 2849, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32940849
7.
Development of a conceptual model and patient-reported outcome measures for assessing symptoms and functioning in patients with heart failure.
Qual Life Res
; 29(10): 2835-2848, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32468405
8.
Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed/refractory multiple myeloma in the DREAMM-2 study.
Front Oncol
; 13: 1274659, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38144529
9.
A toolbox of different approaches to analyze and present PRO-CTCAE data in oncology studies.
J Natl Cancer Inst
; 115(5): 586-596, 2023 05 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36715639
10.
Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study.
Leuk Lymphoma
; 64(2): 398-406, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36408998
11.
Assessing the treatment pattern, health care resource utilisation, and economic burden of multiple myeloma in France using the Système National des Données de Santé (SNDS) database: a retrospective cohort study.
Eur J Health Econ
; 24(3): 321-333, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35610398
12.
Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: results from a discrete choice experiment.
Front Med (Lausanne)
; 10: 1271657, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38076274
13.
Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma.
J Adv Pract Oncol
; 14(6): 503-518, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37808071
14.
Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study.
Hemasphere
; 7(11): e966, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37901848
15.
Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma.
Ann Allergy Asthma Immunol
; 109(1): 59-64, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22727159
16.
Patient Perspectives of the Social, Emotional and Functional Impact of Alopecia Areata: A Systematic Literature Review.
Dermatol Ther (Heidelb)
; 11(3): 867-883, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33770385
17.
Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States.
Clinicoecon Outcomes Res
; 13: 789-800, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34531667
18.
DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma.
Adv Ther
; 38(11): 5501-5518, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34561812
19.
Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis.
Expert Rev Hematol
; 14(12): 1137-1145, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34465265
20.
The Burden of Congestion in Patients Hospitalized With Acute Decompensated Heart Failure.
Am J Cardiol
; 124(4): 545-553, 2019 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31208702